About Brenton Saunders
Form D filings for OcuTerra Therapeutics from 2023 to 2024 list Brenton Saunders as director.
Brenton Saunders first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Brenton Saunders in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Brenton Saunders works with at each company, as listed on that company's latest Form D.
OcuTerra Therapeutics, Inc. · Form D/A, Feb 22, 2024
KB
Kerrie Brady
Chief Executive Officer and director
DE
D. Edwards
Executive officer
RS
Robin Steele
Director
DT
David Tanzer
Executive officer
WK
William Koster
Director
BF
Bruce Failing
Director
BR
Barbara Ryan
Director
RR
Robert Ruffolo
Director
WS
William Steinkrauss
Executive officer